Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Beximco Delivers First Cut-Price Generic Paxlovid

Executive Summary

Bangladesh’s Beximco signed off 2021 on a high launching the first generic version of Pfizer’s Paxlovid at about $186 for a five-day treatment course and claimed that it has ‘adequate capacities' for exports as well.

You may also be interested in...



Generics Industry At The Forefront In War Against COVID-19 In 2021

As the COVID-19 pandemic continued in 2021, the off-patent industry stepped in to provide relief in a variety of ways, whether through securing supplies of essential medicines or helping to manufacture and distribute newly-developed treatments.

Pfizer’s Bourla On Paxlovid Patent Deal And Why A Similar Approach Won't Work For Comirnaty

Pfizer CEO Albert Bourla discussed the emergency use authorization filing for Paxlovid, expanding access to the COVID-19 pill in lower income countries and booster shots, at the STAT Summit.

Beximco Launches World’s First Molnupiravir Generic

Bangladesh’s Beximco has launched the world’s first molnupiravir generic, to be marketed as Emorivir, following an emergency use authorization by the local regulator. The company told Generics Bulletin it was able to manufacture and sell its version of the MSD oral COVID-19 treatment thanks to the WTO’s TRIPS waiver for less economically developed countries.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB151524

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel